GSK PLC 18 March 2024 Issued: 16 March 2024, London UK Positive RUBY phase III data show potential for Jemperli (dostarlimab) combinations...
GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of ...
GSK PLC 13 March 2024 GSK plc (the 'Company') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name...
GSK PLC 08 March 2024 GSK plc Board Committee Change GSK plc today announces the following change to its Board Committee membership with...
GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma. GSK is a Brentfo ...
GSK PLC 07 March 2024 Issued: 07 March 2024, London UK GSK announces positive results from DREAMM-8 phase III trial for Blenrep versus...
GSK PLC 06 March 2024 Issued: 6 March 2024, London UK ViiV Healthcare announces interim data at CROI indicating superior efficacy of...
GSK PLC 05 March 2024 Issued: 5 March 2024, London UK GSK plc 2023 Annual Report on Form 20-F In accordance with Section 203.01 of the...
GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of c ...
GSK PLC 05 March 2024 - Issued: 4 March 2024, London UK ViiV Healthcare presents phase I clinical trial findings of a cabotegravir...
GSK PLC 01 March 2024 GSK plc Total Voting Rights and Capital In conformity with the Financial Conduct Authority's Disclosure Guidance and...
GSK PLC 01 March 2024 GSK plc (the 'Company') Publication of Annual Report 2023 The Company has today published on its website...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.